Form 4: Vigil Neuroscience CFO Receives Repriced Stock Options

Jennifer Lynn Ziolkowski, CFO of Vigil Neuroscience, receives repriced stock options and additional stock option awards under the company's 2021 Stock Option and Incentive Plan.

Summary

• Jennifer Lynn Ziolkowski, the Chief Financial Officer of Vigil Neuroscience, Inc., has been granted repriced stock options and new stock option awards.
• The transactions occurred on May 3, 2024, under the company's 2021 Stock Option and Incentive Plan.
• The repricing involved existing stock option awards, with the exercise price adjusted to $3.03 per share, reflecting the fair market value on the effective date.
• Ziolkowski received repriced options for 110,000 shares and 135,000 shares, and new options for 110,000 shares and 135,000 shares.
• The repriced options will revert to their original exercise price if exercised during the Retention Period, which is defined as the earliest of one year from the effective date, a Sale Event, termination of service by the company without cause or due to death/disability, or termination of service for Good Reason.
• The options vest in 48 equal monthly installments, with vesting starting on April 1, 2022, for the first award and April 1, 2023, for the second award.
• The expiration date for the options is March 1, 2032, and March 1, 2033.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The repricing and granting of new options suggest a commitment to incentivizing the CFO, but the potential negative perception from shareholders regarding the repricing keeps the sentiment from being overly positive.

Positives

• The repricing of stock options may incentivize the CFO to improve company performance.
• The vesting schedule encourages long-term commitment from the CFO.
• The Retention Period provides additional protection for the company in certain scenarios.

Risks

• The repricing of stock options could be viewed negatively by shareholders if the original options were already underwater.
• The Retention Period conditions could create uncertainty for the CFO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the stock options.

Industry Context

Stock option repricing is a common practice in the biotech industry to retain and incentivize key executives, especially when the company's stock price has declined. This ensures that the options remain a valuable incentive for the executive.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like BioNTech and Moderna also use stock options to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms, aiming to balance incentivization with shareholder value.

Stakeholder Impact

• Shareholders may view the repricing of stock options with mixed feelings, depending on their perspective on executive compensation and company performance.
• Employees may see the repricing as a positive sign of the company's commitment to its leadership.

Key Dates